Post-transplant lymphoproliferative disorders in liver transplanted patients: A single-centre experience

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2383-2391

  Marino, Dario ^a   Burra, P ^b   Boccagni, P ^b   Calabrese, F ^b   Canova, F ^a   Trentin, C ^a   Boso, C ^a   Solda C ^a   Angeli, P ^b   Aversa, S M L ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chemotherapy; Liver transplantation; Post transplant lymphoproliferative disorders

Indexed keywords

BLEOMYCIN; BRASSICA EXTRACT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALIPLATIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EXPERIENCE; FEMALE; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; NONHODGKIN LYMPHOMA; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; WORLD HEALTH ORGANIZATION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE;

EID: 77955082698     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Gao SZ, Chaparro SV, Perloth M, Montoya J, Miller JL, Dimiceli S, Hastie T, Oyer PE and Shoroeder J: Posttransplantation lymphoproliferative disease in heart and heart- lung transplant recipient: 30-year experience at Stanford University. J Heart Transplant 22: 505-514, 2003.
2. Pirsch JD, Miller J, Deierhoi MH, Vincenti F and Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63(7): 977-983, 1997. (Pubitemid 27173021)
3. Weisner RH: A long term comparison of tacrolimus (FK 506) versus cyclosporine in liver transplantation : a report of the US FK506 Study Group. Transplantation 66: 493-499, 1998.
4. Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW and Ament ME: The effect of immuno-suppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 70(1): 94-99, 2000. (Pubitemid 30490758)
5. Dror Y, Greenberg M, Taylor G, Superina R, Hébert D, West L, Connolly B, Sena L, Allen U and Weitzman S: Lymphoproliferative disorders after organ transplantation in children. Transplantation 67(7): 990-998, 1999.
6. Libertiny G, Watson CJ, Gray DW, Welsh KI and Morris PJ: Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 88(10): 1330-1334, 2001.
7. Opelz G and Henderson R: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342(8886-8887): 1514-1516, 1993.
8. Purtilo DT: Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet 1(8163): 300-303, 1980.
9. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E et al: Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321(16): 1080-1085, 1989.
10. Hanto DW, Frizzera G, Gajl-Peczalska J, Purtilo DT, Klein G, Simmons RL and Najarian JS: The Epstein-Barr virus (EBV) in the pathogenesis of posttransplant lymphoma. Transplant Proc 13: 756-760, 1981. (Pubitemid 11159233)
11. Wasson S, Zafar MN, Best J and Reddy HK: Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-centre experience. J Cardiovasc Pharmacol Ther 11(1): 77-83, 2006.
12. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA and Tsai DE: Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 6: 569-576, 2006.
13. Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B and Oertel S: Chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with a single-agent rituximab. Transplantation 83: 912-918, 2007.
14. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE and Bradley JA: Anthracycline-based chemotherapy as first-line treatment in adults with malignant post transplant lymphoproliferative disorder after solid organ transplantation. Transplantation 82(3): 375-381, 2006.
15. Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaegle ML and Meyer C: Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 134(6): 602-612, 2006.
16. Buadi F, Heyeman MR, Gocke C, Rapaport A, Hakimian R, Bartlett S and Sarkoode-Adoo C: Treatment and outcome of posttransplant lymphoproliferative disease: a single institution study. Am J Hematol 82(3): 208-214, 2007.
17. Patel H, Vogl DT, Aqui N, Shaked A, Olthoff K, Markmann J, Reddy R, Stadtmauer EA, Schuster S and Tsai DE: Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases. Leuk Lymphoma 48(5): 885-891, 2007.
18. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA and Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7(11): 1630-6, 1989. Erratum in: J Clin Oncol 8(9): 1602, 1990.
19. A predictive model for aggressive non-Hodgkin lymphoma. The International Non-Hodgkin Lymphoma Prognostic Factors Project. N Engl J Med 329(14): 987-994, 1993.
20. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6): 649-655, 1982.
21. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; The International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 25(5): 579-586, 2007.
22. Harris NL, Swerdlow SH and Frizzera G: Post transplant lymphoproliferative disorders; in Jaffe ES, Harris NL, Stein H and Varldman JW: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue. IARC Press, Lyon pp. 264-269, 2001.
23. Bindl JM and Warnke RA: Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars. Am J Clin Pathol 85(4): 490-493, 1986.
24. Olivieri A, Santini G, Patti C, Chisesi T, De Souza C, Rubagotti A, Aversa A, Bilio A, Porcellini A, Candela M, Centurioni R, Congiu AM, Brunori AM, Nati S, Spriano M, Vimercati M, Marino G, Contu A, Tedeschi L, Maiolino I, Crugnolo M and Sertoli MR: Up-front high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non Hodgkin's lymphoma: long-term result by the NHLCSG. Ann Oncol 16: 1941-1948, 2005.
25. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW and Rosenberg SA: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20: 630-637, 2002.
26. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23): 2343-2351, 2004.
27. Ganzina F: 4 Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10(1): 1-22, 1983.
28. Aversa SML, Stragliotto S, Marino D, Calabrese F, Rigotti P, Marchini F, Gambino A, Feltrin G, Boso C, Canova F, Soldà C, Mazzarotto R and Burra P: Post-transplant lymphoproliferative disorders (PTLD) after heart or kidney transplantation at a single centre: presentation and response to treatment. Acta Haematol 120(1): 36-46, 2008.
29. Opelz G and Dohler B: Lymphoma after solid organ transplantation: a Collaborative Transplant Study Report. Am J Transplant 4: 222-230, 2003.
30. Burra P, Buda A, Livi U, Rigotti P, Zanus G, Calabrese F, Caforio A, Menin C, Canova D, Farinati F and Aversa SML: Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection. Eur J Gastr Hepatol 18: 1065-1070, 2006.
31. Duvoux C, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hezode C, Gaulard F, Miguet JP, Larrey D, Dhumeaux D and Cherqui D: Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 74: 1103-1109, 2002.
32. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ, Homan van der Heide JJ, Veeger NJ, Kluin PM and Kluin-Nelemans HC: Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 19(3): 327-334, 2005.
33. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, Eghtesad B, Marsh W, Cacciarelli T, Fontes P, Abu-Elmagd K, Sindhi R, Demetris J and Fung J: Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 236(4): 429-36; discussion 436-437, 2002.
34. Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, Hoyer P, Koepf S, Kraemer U, Laube GF, Müller-Wiefel DE, Netz H, Pohl M, Toenshoff B, Wagner HJ, Wallot M, Weite K, Melter M, Offner G and Klein C: CNS or bone marrow involvement as risk factors for poor survival in posttransplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 25(31): 4902-4908, 2007.
35. Bower M: The management of lymphoma in the immunosuppressed patient. Best Pract Res Clin Haematol 15(3): 517-532, 2002.
36. Mamzer-Bruneel MF, Lomé C, Morelon E, Levy V, Bourquelot P, Jacobs F, Gessain A, Mac Intyre E, Brousse N, Kreis H and Hermine O: Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 18(21): 3622-3632, 2000.
37. Choquet S, Trappe R, Leblond V, Jäger U, Davi F and Oertel S: CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92(2): 273-274, 2007. (Pubitemid 46852438)
38. Gonzalez-Barca E, Domingo-Domenech E, Gomez-Codina J, Capote F, Flores E, Briones J, Salar A, Panizo C, Montalban C, Ribera JM, Caballero D, Muñoz A, Gallur L, Canales MA, Fernandez P, Encuentra M and Fernandez de Sevilla A: First-line treatment with rituximab improves survival of patients with posttransplant lymphoproliferative disease (PTLD). Blood 104: Abstract No: 1406, 2004.
39. Ferry CK, Maillard A, Agbalika F et al: Treatment of B- lymphoproliferative disorder after hematopoietic stem cell transplantation. Role and immunological follow-up of rituximab. Blood 100: Abstract No: 420, 2002.
40. Morrison VA, Bartlett N, Dunn DL and Peterson BA: Rituximab therapy for post-transplant lymphoproliferative disorders (PTLD): preliminary outcome results. Proc of ASCO Ann Meet: Abstract No: 1177, 2001.
41. Horwitz SM, Tsai DE, Twist C et al: Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: a prospective trial in adults and children. Proc Annu Meet Am Assoc Cancer Res 20: Abstract No. 284, 2001.
42. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Váry M, Babel N, Trappe RU, Jonas S, Hummel M, Anagnostopoulos I, Dörken B and Riess HB: Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5(12): 2901-2906, 2005.
43. Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L and Milpied N: Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 107(8): 3053-3057, 2006.
44. Trappe RU, Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H and Oertel S: Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: the role of single-agent rituximab. Transplantation 84(12): 1708-1712, 2007.
45. Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ and Reyes J: Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 66(8): 1047-1052, 1998. (Pubitemid 28513385)
46. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL and Raphael M: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16(6): 2052-2059, 1998.
47. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ and Swerdlow SH: Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 24(3): 375-385, 2000.
48. Borges E, Ferry JA and Friedmann AM: Epstein Barr virus negative precursor B-cell lymphoblastic lymphoma after liver transplantation: a unique form of transplantation disease. Transplantation 73: 541-543, 2002. (Pubitemid 34193611)
49. Ben-Ari Z, Amlot P, Lachmanan SR, Tur-Kaspa R, Rolles K and Burroughs AK: Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl Surg 5(3): 184-191, 1999. (Pubitemid 29217988)
50. Norin S, Kimby E, Ericzon BG, Christensson B, Sander B, Söderdahl G and Hägglund H: Posttransplant lymphoma - a single-center experience of 500 liver transplantations. Med Oncol 21(3): 273-284, 2004.
51. Lorenzini S, Andreone P, Gramenzi A, Morelli C, Zinzani PL, Grazi GL, Pileri S, Baccarani M, Tura S and Bernardi M: Posttransplant lymphoproliferative disorders in liver-transplanted patients: a report of four cases. Transplant Proc 38(5): 1477-1480, 2006.
52. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR and Habermann TM: Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 6(5 Pt 1): 1017-1024, 2006.
53. Avolio AW, Agnes S, Barbarino R, Magalini SC, Frongillo F, Pagano L, Larocca LM, Pompili M, Caira M, Sollazzi L and Castagneto M: Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series. Transplant Proc 39(6): 1956-1960, 2007.